Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Peking University People's Hospital
With
University of Southern California
Previous studies have shown the feasibility of detecting mutation status by circulating tumor DNA (ctDNA)in non-small cell lung cancer (NSCLC) patients. However, no clinical standard method has been established, and most previous studies were lack of prospective clinical data and aimed at advanced NSCLC.
We plan to perform a prospective study including consecutive cases of NSCLC patients who underwent surgical treatments. Primary tumor and plasma samples were collected in each patients and gene mutation analysis were performed immediately after surgery. We utilized the targeted DNA sequencing with a next-generation sequencing (NGS) platform to detect driver somatic mutations in matched tumor DNA (tDNA) and plasma ctDNA samples with matched white blood cell (WBC) DNA as a control. A panel of genes were identified.
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Patient who is confirmed primary lung cancer by frozen pathologic histology
Both the fresh tissue tumor and plasma samples are collected for analysis
You may not be if
Patients who received any treatment prior to resection
Patients who have a history of malignancy
Paraffin embedded section confirmed small cell lung cancer or unclassified carcinoma